ROSE Diagnostics reports $2.2M sold in new $3M equity offering
A September 15th SEC filing reports $2,208,750 sold since the Carlsbad diagnostics developer began the equity offering on July 10th.
By RuntimeWire Staff · Published
Primary source: U.S. Securities and Exchange Commission
Why it matters
The financing gives an experienced diagnostics team more capital to test whether a five-minute adequacy check can prevent repeat lung biopsies. An earlier SEC-filed offering memorandum said ROSE's test cartridge was not yet FDA cleared.
Andrew Morris-led ROSE Diagnostics has sold $2,208,750 toward a $3 million equity offering, according to a Form D filed with the SEC on September 15th. The first sale took place on July 10th, making the disclosure a look at financing activity that began about two months earlier rather than a same-day close.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.